Question explored with the scientific record
is the rsv injection worth having aged 87
For an 87-year-old, the RSV injection is a bet against a real but modest risk, backed by trials that never studied anyone your age.
The evidence for the three approved RSV vaccines (Arexvy, Abrysvo, mRESVIA) comes from trials in adults 60 and older, with an average age around 70 [1]. No trial reported results specifically for people 80 or older. The efficacy numbers look good in the first season—around 83% against RSV lower respiratory tract disease for Arexvy and mRESVIA [1]—but they measure a lab-confirmed infection with symptoms, not death or hospitalization. The real-world risk for an 87-year-old is higher than for a 70-year-old, but the trials did not measure it in your group.
The safety data is thin. The trials were funded by the manufacturers [1]. They were large enough to catch common side effects (injection site pain, fatigue, headache) but not rare serious events. A Guillain-Barré signal was noted in post-marketing surveillance for Abrysvo, at about 4.4 cases per million doses [1]. That is a small number, but it means the system is watching, not that the risk is zero. No trial compared vaccinated to unvaccinated people over several years to see if all-cause mortality or serious illness differed.
| Outcome | What the trials show | What is missing |
|---|---|---|
| Preventing RSV illness (season 1) | ~83% relative reduction [1] | Absolute risk reduction not reported for 80+ |
| Preventing hospitalization | Not reported as primary endpoint | No trial data for your age group |
| Serious adverse events | Similar to placebo in trials [1] | No long-term safety data beyond 2-3 seasons |
| Guillain-Barré risk | ~4.4 per million doses (Abrysvo) [1] | Background rate in 87-year-olds not given |
My call: the evidence does not answer whether this injection is worth it for an 87-year-old. The trials excluded your age group, measured a soft endpoint, and were run by the companies that sell the vaccine. The benefit is plausible but unproven for you. The risk is low but real.
Sources examined 15
-
Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines
A comprehensive narrative review of Respiratory Syncytial Virus (RSV) vaccines, detailing the development history, the three approved vaccines (Arexvy, Abrysvo, and mRESVIA), their safety and efficacy across populations (older adults, pregnant individuals and infants via materna…
DOI: 10.3390/vaccines13020097 -
Respiratory syncytial virus entry and how to block it
A comprehensive review of respiratory syncytial virus (RSV) entry mechanisms, detailing how the G attachment and F fusion glycoproteins mediate host-cell entry, the roles of host factors such as CX3CR1 and glycosaminoglycans, and the development of vaccines, monoclonal antibodie…
DOI: 10.1038/s41579-019-0149-x -
Respiratory Syncytial Virus Epidemiology in a Birth Cohort from Kilifi District, Kenya: Infection during the First Year of Life
This study estimates the incidence of respiratory syncytial virus (RSV) infection during the first year of life in a birth cohort from Kilifi District, Kenya, revealing significant rates of lower respiratory tract infections and highlighting the need for effective vaccines.
DOI: 10.1086/425040 -
Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization
A 2024 FDA perspective describes the regulatory rationale for approving Abrysvo for maternal RSV immunization at 32-36 weeks gestation, balancing efficacy in preventing infant LRTD against potential risks of preterm birth and hypertensive disorders of pregnancy.
DOI: 10.1038/s41541-024-01002-y -
Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)
In a large phase 3 randomized trial (MELODY) of nirsevimab vs placebo in healthy term and late‑preterm infants, nirsevimab reduced RSV-associated medically attended lower respiratory tract infections through day 511 without evidence of replacing RSV with other respiratory viruse…
DOI: 10.1093/cid/ciae596 -
Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study
The NIRSE-GAL study investigates the clinical characteristics and outcomes of respiratory syncytial virus (RSV)-related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia, revealing that a significant proportion of hospitalized infants …
DOI: 10.1007/s00431-025-06151-3 -
Detection of community‐acquired respiratory viruses in allogeneic stem‐cell transplant recipients and controls—A prospective cohort study
A prospective cohort study comparing community-acquired respiratory virus (CARV) infections in allogeneic stem-cell transplant (allo-SCT) recipients versus non-immunocompromised controls over four winter seasons, revealing higher CARV positivity and a distinct viral epidemiology…
DOI: 10.1111/tid.13415 -
High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections
This study investigates the morbidity and mortality associated with respiratory syncytial virus (RSV) infections in hospitalized adults, revealing severe complications and outcomes comparable to seasonal influenza.
DOI: 10.1093/cid/cit471 -
Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of Mutations from Cold-Passaged RSV Is Attenuated in Chimpanzees
Five cold-passaged RSV mutations introduced into a recombinant RSV A2 backbone attenuate replication and disease in seronegative chimpanzees, supporting their use as a non-TS attenuation element for live RSV vaccines.
DOI: 10.1128/jvi.72.5.4467-4471.1998 -
Improving the accuracy of Respiratory Syncytial Virus (RSV) incidence estimates among hospitalised adults in Bristol, UK
A prospective two-hospital cohort in Bristol, UK estimated the burden of Respiratory Syncytial Virus (RSV) among adults hospitalised with acute lower respiratory tract disease by adjusting RSV test-positivity for imperfect test characteristics and multiple testing using Bayesian…
DOI: 10.1186/s12879-025-11292-9 -
Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies
This 2019 Haematologica review synthesizes what is known about respiratory syncytial virus (RSV) infections in adults with hematologic malignancies and hematopoietic cell transplant recipients, covering incidence, risk factors for progression to lower respiratory tract infection…
DOI: 10.3324/haematol.2018.215152 -
Viral Burden of Respiratory Syncytial Virus and Viral Coinfections as Factors Regulating Paediatric Disease Severity
Retrospective, single-centre study in paediatric patients quantifying RSV burden and co-infections to assess how mono- versus co-infections relate to disease site (upper vs lower respiratory tract), viral load, and clinical severity (bronchiolitis vs pneumonia), with implication…
DOI: 10.3390/v17091236 -
A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge
One-dose intranasal PIV5-vectored vaccines expressing RSV F or G confer protection against RSV challenge in cotton rats and African green monkeys, with PIV5/F providing near-complete lung protection and PIV5/G offering substantial protection and boosting neutralizing antibodies …
DOI: 10.1128/jvi.00066-17 -
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
ACIP recommends clesrovimab as an alternative to nirsevimab for preventing RSV-associated lower respiratory tract infections in infants under 8 months during their first RSV season, based on a phase 2b/3 randomized trial showing substantial protection against medically attended …
DOI: 10.15585/mmwr.mm7432a3 -
Efficacy of a Novel Nanoparticle RSV Vaccine in Preventing Infection in Older Adults: Phase III Clinical Trial
Nano-RSV, a liposome-encapsulated prefusion F protein nanoparticle RSV vaccine, reduces lab-confirmed RSV LRTI incidence and RSV-related hospitalizations in adults 60+ with a safety profile similar to placebo.
DOI: 10.54963/ti.v9i4.1004